Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Chronic obstructive pulmonary disease (COPD) exacerbations are risk factors for disease progression and short-term re- hospitalizations. We propose a randomized controlled trial to evaluate the efficacy of a one-device multiparameter telemonitoring in reducing functional decline, symptoms, and risk of re-hospitalization of patients discharged after hospitalization for exacerbated COPD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Able to understand and sign the informed consent form.

• Already established diagnosis of COPD according to Global Initiative for Obstructive Lung Disease (GOLD) guidelines.\[13\]

• Diagnosis of COPD exacerbation at admission, according to GOLD guidelines.\[13\]

• Arterial partial pressure of oxygen (PaO2) \< 60 mmHg in ambient air at rest at admission and arterial partial pressure of oxygen (PaO2) \> 60 mmHg in ambient air at rest at discharge, if not on long-term oxygen therapy on ventilation.

• Arterial partial pressure of oxygen (PaO2) \< 55 mmHg on usual oxygen supplement (L/min) and arterial partial pressure of oxygen (PaO2) \> 60 mmHg on oxygen supplement at discharge, if already on long-term oxygen therapy on ventilation.

⁃ g) Age \<= 90 and \>= 18 years old at randomization.

Locations
Other Locations
Italy
SC Pneumologia, Azienda Sanitaria Universitaria Giuliano-Isontina
RECRUITING
Trieste
Contact Information
Primary
Francesco Salton, MD
francesco.salton@gmail.com
00390403994667
Backup
Msrco Confalonieri, MD
mconfalonieri@units.it
00390403994667
Time Frame
Start Date: 2024-03-29
Estimated Completion Date: 2026-09-30
Participants
Target number of participants: 60
Treatments
Experimental: Telemonitoring
No_intervention: Standard of care
Sponsors
Leads: University of Trieste

This content was sourced from clinicaltrials.gov